EFFECTS OF COMBINED CHEMOTHERAPY AND INTENSITY-MODULATED RADIOTHERAPY ON PULMONARY FUNCTION AND LONG-TERM OUTCOMES IN ATHLETES WITH THORACIC TUMORS

Abstract

Objective: This study aims to assess the effects of concurrent induction chemotherapy and intensity-modulated radiation therapy (IMRT) on lung function and long-term outcomes in athletes diagnosed with thoracic tumors. Methods: From February 2018 to May 2023, 84 athletes with thoracic tumors were prospectively analyzed in our oncology department. Participants were dynamically and randomly assigned into two groups: a control group (40 cases) treated solely with IMRT and a study group (44 cases) treated with both induction chemotherapy and IMRT. Measurements of tumor markers (CEA, NSE, CA199, CA125), liver and kidney functions (ALT, AST, TBiL, DBiL), and lung function (TV, MVV, FVC, MMEF) were taken before treatment and three months post-treatment. Short-term (DCR, ORR) and long-term efficacy (OS, PFS), alongside adverse reactions, were also evaluated. Results: Significant reductions in tumor markers and liver and kidney function damage were noted post-treatment, alongside improvements in lung volume and ventilation functions. The study group showed superior outcomes in tumor response rates (ORR and DCR), as well as in overall survival and progression-free survival, compared to the control group. Although the study group experienced a higher incidence of adverse reactions such as insomnia, nausea, and myelosuppression, these were not statistically significant when compared to the control group. Conclusion: The combined use of induction chemotherapy and IMRT in treating thoracic tumors in athletes enhances lung function and overall treatment efficacy without significantly increasing adverse reactions. This approach promises beneficial impacts on athletes' health, enabling better recovery and return to sports activities, thus supporting its application in clinical settings specialized in sports medicine.